Calls for urgent home support packages after aged care reform delay

The government is under pressure to fund at least 20,000 new at-home care packages for older Australians who need additional support, after the implementation of sweeping sector-wide aged care reforms were postponed.
A group of 10 crossbenchers have written to the government calling for the additional packages to be made available from next month, a push that has been backed by the aged care sector and advocates.
Under the aged care reforms — which passed parliament in November with bipartisan support — 83,000 home support packages were due to be rolled out from July.
But the government announced last week that it would delay the implementation of the wider reforms until November to allow for a smooth transition and allay concerns from the sector.
While providers and advocates welcomed the extension for the most part, they have raised concerns that the four-month delay would worsen the existing backlog of people waiting for at-home supports.
About 80,000 people are currently on the waitlist for home care packages, with some people waiting a year for their correct supports to help with things like cleaning, cooking and showering.
Independent Senator David Pocock, who was part of the group that wrote the letter to the government, warned on Wednesday that "people are dying on the waitlist".
While he said delaying the majority of reforms was a good thing, he argued there is "absolutely no reason" to hold off on the home care packages.
"The government has already budgeted for this," he said.
"They need to bring that part of the reform forward so people can actually age at home with dignity rather than ending up in hospital or in aged care facilities, which are far more expensive."
Fellow independent Helen Haines said the longer the wait for services, the bigger the backlog will grow.
"The longer that they wait, the higher the chances are of further deterioration in their health and in many cases, people have a premature entry into residential aged care," she said.
Canberra resident Kaye Pritchard has seen first-hand what the waitlist for at-home support means for the people that need it.
Her cousin, Robin Rawson, was 93 when she died in April last year after being approved for a level four home care package — the highest one available.
She had been told it would take six to nine months before she would be able to access that additional support.
"I can remember her saying at the time, 'well, that's not much use to me because I'm going to be dead by then,'" Ms Pritchard said.
"And she certainly was within the next couple of months. She deteriorated and passed away without ever receiving any of the benefits that she needed in those crucial last weeks of her life."
Ms Pritchard said her cousin wanted to stay at home and the additional supports would have given her peace of mind that she could "die with dignity".
"Six to nine months to wait for a package for someone who is terminally ill is just not good enough," she said.
The reworked Support at Home Program is designed to shorten wait times for home care packages and lift funding for the highest classification of need up from $60,000 to $78,000 a year.
It will provide support for nursing care, occupational therapy, help with showering or taking medications, and everyday living like cleaning and gardening, as the government aims to help more people stay in their homes for longer.
Those packages will also be subject to greater means testing, which will vary depending on individual circumstances.
Tom Symondson, the chief executive of peak body Ageing Australia, warned that the waitlist would grow to over 100,000 people if the packages are held up until November.
"We need to see packages start to flow," he said. "We just can't have people waiting longer than they already are."
Craig Gear, head of the Older Person Advocacy Network, told the ABC that many people want to be able to age at home.
"And we also know that the residential aged care system, it's under a lot of pressure and it's pretty full at the moment," he said.
"So we need to help support people to stay in their home as long as they can."
Aged Care Minister Sam Rae did not respond to ABC News' request for comment.
But Health and Ageing Minister Mark Butler last week said the government had decided to push back the start date after listening to the sector.
"We need to think about a delay of a few months to ensure that all of the systems are in place to deliver a smooth transition to the new laws, and also that older Australians are fully informed about what those new laws will mean for them," he said.
"Nonetheless, what we see into the future is a once-in-a-generation reform to the aged care system that will deliver high quality, world class aged care services to older Australians who have built this community."

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

News.com.au

an hour ago

• News.com.au

Health Check: It's ‘nothing personal' as major US biotech fund calls time on Syntara

San Francisco's BVF Partners has exited all its ASX investments because they are too small for the fund's mandate Alcidion shares soar 15% on earnings upgrade Optiscan enters 'win-win' supplier collab Syntara (ASX:SNT) CEO Gary Phillips says the exit of a long-term US backer should not be seen as a judgment on the company's late-stage myelofibrosis drug program. In a block trade the San Francisco BVF Partners has disposed of its $5 million, 6%, Syntara stake. The shares were taken up by some of Syntara's existing institutional holders. BVF's exit last week sent Syntara shares down by 25%, despite the company's previous Friday's positive update on its phase II myelofibrosis trial update. Phillips says the trial news created a 'liquidity event' which BVF availed of. But it was not a case of BVF (as in Biotech Value Fund) spurning Syntara's drug program. Rather, the fund grew to the extent where it can't justify a minimum investment below US$30-50 million. 'They always liked our science,' Phillips says. 'They have visited our labs and were always encouraged, but they just got bigger and bigger.' With US$9 billion of assets, BVF has called time on all its ASX investments. In May BVF divested its $3 million in Actinogen Medical (ASX:ACW), also via a block trade. The fund had also invested in Opthea (ASX:OPT), but got off before the eye drug developer's' trials went pear shaped. BVF also invested in immune-oncology drug developer Viralytics, famously taken over by Merck for an eyebrow-raising $500 million in 2018. Syntara's blood cancer program looks the goods Syntara's 'liquidly event' stemmed from further data from its phase II myelofibrosis trial, evaluating its drug candidate SNT-5505 in combo with the standard-of-care drug ruxolitinib. The patients had been treated with ruxolitinib, so had symptoms such as enlarged spleen size and blood counts 'indicative of high disease burden'. The results showed eight of 11 evaluable patients (73%) achieved a reduction of more than 50% at 24 weeks, as measured by a standard gauge called TSS50. Four out of nine patients (44%) had a spleen volume reduction of 25% at week 24 or beyond. The ongoing trial enrolled 16 patients with intermediate or high-risk myelofibrosis, for 52 weeks of treatment. However, five dropped out by the 24-week mark. This is a 'withdrawal rate consistent with that seen in other myelofibrosis studies of patients with similar disease severity." Eight patients reaching 38 weeks showed and average 56% reduction in symptoms, while five reaching 52 weeks exhibited a 63% decline. Syntara intends to chat with the FDA in the September quarter about the design of a pivotal phase 2c/3 study. Too much of a good thing for Immutep? With four trial updates on separate programs in less than two months, immunology drug play Immutep (ASX:IMM) must also feel underappreciated. Immutep stock has fallen around 10% in this period and trades at close to five-year lows, despite the upbeat clinical vibes. Too much activity from the multi-tentacled Immutep confusing investors, perhaps? Today, Immutep said a phase I autoimmune study showed 'significant T-cell suppression', thus highlighting potential efficacy of its candidate IMP-761. Initial data from placebo-controlled, double-blinded effort also showed good safety at the highest dosing level to date. By stimulating the LAG-3 (lymphocyte-activation gene-3) agonist antibody, IMP-761 promises to treat conditions including rheumatoid arthritis, Type 1 diabetes and multiple sclerosis. Since May 5 Immutep also has updated investors on its head and neck cancer, lung cancer and soft tissue sarcoma trials. Miya My! Alcidion has upgraded earnings Hospital patient management software supplier Alcidion (ASX:ALC) has upped its full-year earnings outlook, with strong take-up of its flagship Miya prompting clients to adopt its broader wares. 'Over the past few months this has resulted in several customers of varying size seeking extensions or module upgrades," CEO Kate Quirke says. "This has contributed to our improved financial position." Having guided to earnings before interest, tax depreciation and amortisation of $3 million, the company now expects the number to exceed $4.5 million (for the year to June 30 2025). The company earlier guided to revenue of at least $40 million. Alcidion provides to more than 400 hospitals and 87 healthcare organisations in the UK, here and New Zealand. In the UK, the most capacious market, the beloved National Health Service (NHS) is being merged with Department of Health and Social Care. This poses both threat to – and opportunities for – Alcidion, given it sells to NHS organisations. In April, Quirke said the push for more NHS productivity with fewer staff was likely to mean greater demand for Alcidion's digital platforms. 'I see the opportunity increasing,' she said. 'But we are waiting to see what the ten-year plan indicates in terms of where the priority areas are.' PYC gets FDA OK PYC Therapeutics (ASX:PYC) has provided evidence that the FDA continues to function, with the agency approving the company's proposed trial design at a preliminary (Type B) meeting. The company currently is undergoing a phase 1-2 trial of its drug candidate VP-001, to treat the blinding eye disease retinitis pigmentosa type 11 (RP11). With positive data to date, PYC wants to progress to a phase2/3 study pitched at FDA approval. The FDA says PYC can use similar endpoints and says trial design features (such as use of a sham arm and inclusion exclusion criteria) are OK as well. The company will use this guidance to finalise its proposed registrational study design. Tryptamine study aims to put binge eating disorder to BED Meanwhile, Tryptamine Therapeutics (ASX:TYP) has won ethics approval for the world's first trial, to test intravenously infused psilocin for binge eating disorder (BED). BED is the most common eating disorder in the US and second most common here. BED results in multiple other conditions including depression, anxiety, PTSD (post-traumatic stress disorder) and compulsive behaviours. A collaboration with Swinburne University, the local trial will enrol 12 patients and administer them with with Tryptamine's drug candite TRP-8803. They will be given two doses 14 days apart and also undergo psychotherapy. The trial has started recruiting, with first dosing expected in the September quarter. Investors can expect top-line results before the year is out. The good OIL on a 'win-win' collab Optiscan (ASX:OIL) has entered a five-year collaboration agreement with the US based Long Grove Pharmaceuticals, which provides a contrast agent for Optiscan's fluorescence-based endomicroscopic imaging systems. The idea of the collab is to use Long Grove's fluorescein drug, AK-FLUOR, with Optiscan's imaging technology in clinical studies. This potentially will identify new applications for the drug and expedite regulatory submissions. On the Optiscan side of things, the data should support the company' efforts to win FDA approval for its Invue device. Invue enables surgeons to gain real-time pathology insights and make on-the-spot decisions. Optiscan CEO Dr Camile Farah dubs the agreement a 'clear-cut win-win for both companies' development strategies'.

ABC News

3 hours ago

• ABC News

Meet the breast cancer survivors on a 'slightly unhinged' but growing support mission

When Carol Smith was diagnosed with breast cancer in 2018, she found solace in her connection online with a woman going through the same treatment. As well as shock, confusion and a search for answers, the diagnosis and new friendship set off a chain of events that led to a "slightly unhinged" development — she joined the "Shitty Titty Committee" in her now home city of Busselton, Western Australia, a movement to make sure women don't struggle alone. Ms Smith was 36 when she discovered a lump on her left breast. "When they sat me down and said, 'You have breast cancer,' my reaction was just shock," she said. "I was just completely numb. Within two weeks, she had her first round of chemotherapy. She turned to the internet to find advice and support from women experiencing the same thing. "I had a lot of friends around me [but] just being able to reassure yourself that this symptom is normal, that this medication is meant to make you feel the way you're feeling, and anything like that that non-cancer people wouldn't be able to understand." Ms Smith threw herself into fundraising after her successful treatment. On the fifth anniversary of her diagnosis in 2023 she held the first Big Boobie Ball in Busselton, which brought local breast cancer survivors and patients together. From there, the Shitty Titty Committee was formed. The support group has grown its membership to about 17 women around the Busselton area. Kate Grainger gave the group its "slightly unhinged" name in 2024. Ms Grainger's breast cancer journey began in 2023 when she travelled from WA's Pilbara region to Busselton Hospital to give birth to her son. There, the expecting mother was given a life-changing diagnosis. "They said, 'You're baby is being born tomorrow' … I started chemo when he was nine days old," she said. She was 1,400 kilometres from home and staying in an Airbnb. But she was overwhelmed by the support of her new community, including another cancer patient who set up a "meal train" of food deliveries. "It was just like giving my heart a hug because I knew I couldn't get up and make my family a meal and I couldn't carry my baby and couldn't hold my two or four-year-old," she said. "I was very unwell for a very long time." Ms Grainger, now 33, had a clear scan in October after long treatment. She said she had turned her attention to helping others via the committee. "I went to my oncologist a couple of months ago and there was this gorgeous woman sitting in the chair having her chemo infusion … she said, 'What's this Shitty Titty Committee?' and I said, 'Oh, it's just a group of us locals who have had the c-bomb dropped on us and we're just stumbling through it together,'" she said. The Cancer Council estimates about 38 people are diagnosed with breast cancer every day in Western Australia. Cancer Council WA supportive care director Melanie Marsh said she was pleased to see country people come together during a "scary" time in their lives. "These support groups in regional areas are just fabulous to be able to bring that face-to-face support for people who need it."

ABC News

4 hours ago

• ABC News

Telstra tower upgrades touted as 'safety issue' by locals in southern Queensland town

A mobile outage caused by 5G upgrades to a Telstra base tower has left many in the Western Downs hub of Dalby in Queensland unable to make or receive calls, texts, or access the internet. Locals have called it a safety issue, while businesses and medical carers have been at a standstill. The town with a population of more than 13,000 people was warned of the disruption last Wednesday via text. Residents like Craig Tobin say the outage, expected to last for up to two weeks, is a "disgrace". "I drove out of Dalby last night until I got signal because my family in Brisbane, elderly parents, didn't know why I didn't have reception for days," he said. "I can't believe people are saying: 'Ah well, we just don't have phones for up to two weeks.' Telstra's regional general manager, May Boisen, said connections like NBN, satellite internet or landline, and calls through wi-fi — as well as other telco providers — have been unaffected. But the impact on locals has been significant. "I have three Telstra devices; I have no signal on all of them," Mr Tobin said. "I've been using my Telstra hotspot at home for my wi-fi … I'm not hooked into the NBN yet, as I moved into my house four weeks ago and am waiting for it to be put on." Dalby Chamber of Commerce's Anna Story said it was a "massive" safety issue and was impacting businesses. Aged care facility BlueCare said staff were unable to give or receive calls from clients, and carers were unable to access client details. "Clients' safety is impacted as we are unable to call them or their family members to see if they are OK," a spokesperson said. "Staff are at risk if something happens to them and they can't call for help. The care provider had purchased an Optus service to work around the problem. Smaller businesses have also vented their frustrations. "I'm so cranky," hairdresser Mel Drier said. "It's been a real mess around for me and has severely impacted my business. "I had a client who cancelled, but I didn't know that because I had no service … I'm having to write down names and numbers and wait until I get home to contact my clients later at night." Many businesses are using cash only, including a medical practice and a local cab company. Demand on the network was growing by 30 per cent year-on-year, according to Telstra. Ms Boisen said the lengthy upgrades and outages were a necessity. "For those that are technically minded, it's actually like a six-sectored mobile base station, which is a big base station," she said. "I'll give you an example. My husband is a diabetic. I don't need the landline, but I have it because mobiles will go down, and we do need to repair mobile base stations. "If we misunderstood what our customers were wanting to use our network for, then we wouldn't be upgrading our network." Triple-0 calls are diverted through other providers' mobile towers, even when called from a Telstra phone. Any calls that have not connected through will be investigated by Telstra. Services are scheduled to come back online progressively by Monday. Full mobile coverage is expected to be impacted until June 30.